| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Di | Eurobio Scientific: 2025 FY revenue | 178 | GlobeNewswire (Europe) | FISCAL YEAR 2025, CONFIRMATION OF STRATEGIC TRANSFORMATION 9% increase in annual revenue to €168 millionDeployment of the Group's strategy: Proprietary products: 35% of revenueInternationalization:... ► Artikel lesen | |
| 14.11.25 | ABL Diagnostics Appoints Eurobio Scientific as Exclusive Distributor for Its VELA Product Line in a Targeted Segment of the French Market | 310 | Business Wire | Regulatory News:
ABL Diagnostics (Euronext Paris: ABLD), a French company specializing in advanced molecular diagnostics, announces the signing of an exclusive distribution agreement with Eurobio... ► Artikel lesen | |
| 01.07.25 | Eurobio Scientific completes the acquisition of Life Science unit of Voden Medical Instruments Spa in Italy | 264 | GlobeNewswire (Europe) | Eurobio Scientific completes the acquisition of Life Science unit of Voden Medical Instruments Spa in Italy Paris, July 1st, 2025 Eurobio Scientific (FR0013240934, ALERS), (FR0013240934, ALERS, PEA-PME... ► Artikel lesen | |
| EUROBIO SCIENTIFIC Aktie jetzt für 0€ handeln | |||||
| 19.05.25 | Eurobio Scientific: EB Development rises above 90% threshold | 750 | GlobeNewswire (Europe) | EB Development rises above 90% threshold Paris, May 19, 2024 - 7:00 pm - Eurobio Scientific (FR0013240934, ALERS, PEA-PME eligible), a leading French group in in vitro medical diagnostics and life... ► Artikel lesen | |
| 28.04.25 | Eurobio Scientific: 2024 annual results | 385 | GlobeNewswire (Europe) | 2024 ANNUAL RESULTS Growth of core business and strategic execution Revenue up 19% to €154 million Organic growth at +9%Proprietary products account for a stable 31% of group revenueInternational... ► Artikel lesen | |
| 05.03.25 | Biovica International: Biovica Signs Agreement With Eurobio Scientific Covering 60 Percent of European Market | 518 | ACCESS Newswire | UPPSALA, SE / ACCESS Newswire / March 5, 2025 / Biovica International (STO:BIOVIC-B)(STO:BIOVIC.B)(FRA:9II) Biovica, active in cancer monitoring, has signed a collaboration agreement with Eurobio Scientific... ► Artikel lesen |
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BAYER | 44,840 | +1,87 % | EQS-PVR: Bayer Aktiengesellschaft: Veröffentlichung gemäß § 40 Abs. 1 WpHG mit dem Ziel der europaweiten Verbreitung | EQS Stimmrechtsmitteilung: Bayer Aktiengesellschaft
Bayer Aktiengesellschaft: Veröffentlichung gemäß § 40 Abs. 1 WpHG mit dem Ziel der europaweiten Verbreitung
27.01.2026... ► Artikel lesen | |
| GILEAD SCIENCES | 120,52 | +0,60 % | Leerink Partners raises Gilead Sciences stock price target to $146 on HIV pipeline | ||
| AURORA CANNABIS | 3,375 | -1,60 % | CBD-Markt auf Wachstumskurs: Neural Therapeutics und Hanf.com positionieren sich strategisch | ||
| SANOFI | 81,02 | +2,21 % | Umsatzwachstum: Sanofi plant Aktienrückkäufe in Höhe von 1.000.000.000 Euro | © Foto: Martin Joppen / SanofiDer französische Arzneimittelhersteller Sanofi teilt am Donnerstag mit, dass er für 2026 ein Umsatzwachstum im hohen einstelligen Prozentbereich erwartet. Grundlage für... ► Artikel lesen | |
| CANOPY GROWTH | 0,926 | -0,32 % | Canopy Growth: Treffer ohne Gewinn - Trading-Tipp wird zurückgezogen | ||
| TILRAY BRANDS | 6,320 | +0,48 % | TILRAY BRANDS INC: Stabilität als Grundlage für den nächsten Schritt | ||
| TEVA | 29,700 | +3,12 % | Teva Pharmaceutical Turns To Profit In Q4, Announces FY26 Outlook | PETAH TIKVA (dpa-AFX) - Teva Pharmaceutical Industries Limited (TEVA), Wednesday announced the fourth quarter financial results, reporting net profit of $480 million, or $0.41 per share, attributable... ► Artikel lesen | |
| VERTEX PHARMACEUTICALS | 398,65 | +0,53 % | Prediction: 2026 Will Be the Year of Vertex Pharmaceuticals | ||
| CRONOS GROUP | 2,082 | -1,51 % | Cronos Group Inc.: Cronos to enter the Netherlands with acquisition of Europe's largest adult-use cannabis company | Cronos to acquire CanAdelaar for up-front cash consideration of US$67.0M1 plus cash earnout of 0.5x normalized EBITDA in 2026 and 2027 Up-front consideration represents approximately 1.4x CanAdelaar... ► Artikel lesen | |
| DOCMORRIS | 6,210 | +1,64 % | DocMorris AG: DocMorris kauft Wandelanleihen mit Fälligkeit 2026 im Nennwert von rund CHF 14.4 Mio. zurück | DocMorris AG
/ Schlagwort(e): Anleihe
DocMorris kauft Wandelanleihen mit Fälligkeit 2026 im Nennwert von rund CHF 14.4 Mio. zurück
26.01.2026 / 18:30 CET/CEST
Frauenfeld... ► Artikel lesen | |
| VIATRIS | 11,380 | +4,21 % | Piper Sandler raises Viatris stock price target to $12 on brand strength | ||
| GRIFOLS | 10,980 | +0,50 % | Grifols Secures FDA Approval To Launch Fesilty In US In First Half Of 2026 | MADRID (dpa-AFX) - Biotest AG, Friday announced that its parent company Grifols, S.A. (GRFS) has received approval from the U.S. Food and Drug Administration for Fesilty, a human fibrinogen... ► Artikel lesen | |
| TONIX PHARMACEUTICALS | 14,600 | 0,00 % | Tonix Presents Positive Phase 3 RESILIENT Data On TONMYA At 2026 Non-Opioid Pain Therapeutics Summit | ||
| KHIRON LIFE SCIENCES | 0,029 | -100,00 % | Khiron Life Sciences Corp: Khiron Life Sciences warrants to expire Nov. 26 | ||
| WUXI BIOLOGICS | 3,871 | -1,59 % | WuXi Biologics and Sinorda Biomedicine Enter Strategic Collaboration to Accelerate Development and Manufacturing of Innovative Bispecific Antibody | SHANGHAI, Jan. 28, 2026 /PRNewswire/ -- WuXi Biologics (2269.HK), a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), and Sinorda Biomedicine today... ► Artikel lesen |